Merck and Co., Inc.-Product Pipeline Review-2015

Merck and Co., Inc.-Product Pipeline Review-2015

  • Products Id :- GMDHC06988CDB
  • |
  • Pages: 370
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Merck & Co., Inc.-Product Pipeline Review-2015


Global Markets Direct's, 'Merck & Co., Inc.-Product Pipeline Review-2015', provides an overview of the Merck & Co., Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Merck & Co., Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of Merck & Co., Inc. including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Merck & Co., Inc.'s human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Merck & Co., Inc.'s pipeline products

Reasons To Buy

Evaluate Merck & Co., Inc.'s strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Merck & Co., Inc. in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Merck & Co., Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Merck & Co., Inc. and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Merck & Co., Inc.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Merck & Co., Inc. and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

Merck & Co., Inc. Snapshot 8

Merck & Co., Inc. Overview 8

Key Information 8

Key Facts 8

Merck & Co., Inc.-Research and Development Overview 9

Key Therapeutic Areas 9

Merck & Co., Inc.-Pipeline Review 20

Pipeline Products by Stage of Development 20

Pipeline Products-Monotherapy 21

Pipeline Products-Combination Treatment Modalities 22

Pipeline Products-Partnered Products 23

Pipeline Products-Out-Licensed Products 26

Merck & Co., Inc.-Pipeline Products Glance 29

Merck & Co., Inc.-Late Stage Pipeline Products 29

Merck & Co., Inc.-Clinical Stage Pipeline Products 33

Merck & Co., Inc.-Early Stage Pipeline Products 37

Merck & Co., Inc.-Unknown Stage Pipeline Products 40

Merck & Co., Inc.-Drug Profiles 41

(ceftolozane sulfate + tazobactam sodium) 41

(lamivudine + raltegravir potassium) 43

diquafosol tetrasodium 44

human papillomavirus (9-valent) vaccine 46

omarigliptin 48

pembrolizumab 50

sugammadex sodium 56

tedizolid phosphate 58

corifollitropin alfa 60

(actoxumab + bezlotoxumab) 62

(doravirine + lamivudine + tenofovir disoproxil fumarate) 63

(ertugliflozin + metformin) 64

(ertugliflozin + sitagliptin) 65

(etoricoxib + tizanidine) 66

(grazoprevir + elbasvir) 67

actoxumab 69

anacetrapib 70

aprepitant 72

asenapine maleate 74

bevenopran 75

bezlotoxumab 77

desloratadine 78

doravirine 79

fidaxomicin 80

insulin glargine 83

letermovir 85

MK-8237 86

MK-8931 88

odanacatib 89

posaconazole 91

rituximab biosimilar 92

solithromycin 93

surotomycin 95

V-212 96

V-920 98

vibegron 101

vorinostat 102

BQ-123 106

dalotuzumab 108

grazoprevir 111

lomerizine 113

lonafarnib 114

mirtazapine ODT 116

MK-1029 117

MK-2206 118

MK-2206 + selumetinib sulfate 121

MK-7622 123

MK-8342B 124

MK-8628 125

narlaprevir 127

relebactam 128

samatasvir 130

temozolomide 132

V-114 134

MK-3682 135

CB-618 136

MK-0752 137

MK-1075 138

MK-2048 139

MK-2248 140

MK-2640 141

MK-4166 142

MK-7680 143

MK-8150 144

MK-8189 145

MK-8242 146

MK-8291 148

MK-8408 149

MK-8507 150

MK-8521 151

MK-8591 152

MK-8666 153

MK-8723 154

MK-8876 155

Monoclonal Antibody for Autoimmune Diseases 156

NB-1008 157

SCH-772984 158

Small Molecule 1 for Human Cytomegalovirus Infection 159

Small Molecule 2 for Human Cytomegalovirus Infection 160

V-160 161

V-180 162

BNC-375 163

CB-027 164

chikungunya vaccine 165

DORA-12 166

Drug to Inhibit 11Beta-HSD1 for Hypertension 167

Drugs to Inhibit CYP11B2 for Cardiovascular Diseases 168

ETP-142 169

GP-4 170

GRA-1 171

J8-CRM197 172

M-867 173

mDX-400 174

MK-4256 175

MK-8745 176

MK-8825 177

MK-8970 178

Monoclonal Antibodies to Inhibit PCSK9 for Hypercholesterolemia 179

MRK-003 180

Oligonucleotides for Viral Infections 181

OTX-009 182

Proteins for Cancer, Autoimmune and Inflammatory diseases 183

PTC-512 184

PTC-725 185

PTC-971 186

respiratory syncytial virus vaccine 187

SCH-412348 189

SCH-546738 190

Small Molecule 3 for Human Cytomegalovirus Infection 191

Small Molecule to Agonize Glucocorticoid Receptor for Respiratory Disorders 192

Small Molecule to Inhibit JAK2 for Myeloproliferative Disorder 193

Small Molecule to Inhibit Kinesin Spindle Protein for Cancer 194

Small Molecule to Inhibit PLK1 for Cancer 195

Small Molecules for Atherosclerosis 196

Small Molecules to Agonize M1 for Alzheimer's Disease 197

Small Molecules to Agonize TLR7/8/9 for Cancer, Alzheimer's Disease and Infectious Disease 199

Small Molecules to Block Cav2.2 Channel for Chronic Pain 200

Small Molecules to Inhibit DHFR for Septicaemia 201

Small Molecules to Inhibit NS5B Polymerase for Hepatitis C 202

Small Molecules to Inhibit Prolyl Hydroxylase for Anemia 203

THPP-1 204

TROX-1 205

XEN-445 206

XL-499 207

Biosimilars for Undisclosed Indication 208

Drug to Target GPCR for Undisclosed Indication 209

hepatitis C vaccine 210

Kibdelomycin A 211

Monoclonal Antibodies for Undisclosed Indication 212

Monoclonal Antibody for Cancer 213

Monoclonal Antibody for Neurology 214

SCH-722984 215

Small Molecules for Undisclosed Indication 216

Small Molecules to Inhibit CGRP Receptor for Migraine 217

Small Molecules to Inhibit DGAT1 for Undisclosed Indication 218

Small Molecules to Inhibit Renin for Undisclosed Indication 219

Small Molecules to Activate sGC for Cardiovascular Disease 220

Merck & Co., Inc.-Pipeline Analysis 221

Merck & Co., Inc.-Pipeline Products by Target 221

Merck & Co., Inc.-Pipeline Products by Route of Administration 227

Merck & Co., Inc.-Pipeline Products by Molecule Type 228

Merck & Co., Inc.-Pipeline Products by Mechanism of Action 230

Merck & Co., Inc.-Recent Pipeline Updates 235

Merck & Co., Inc.-Dormant Projects 298

Merck & Co., Inc.-Dormant Projects 298

Merck & Co., Inc.-Discontinued Pipeline Products 306

Discontinued Pipeline Product Profiles 308

Merck & Co., Inc.-Company Statement 319

Merck & Co., Inc.-Locations And Subsidiaries 322

Head Office 322

Other Locations & Subsidiaries 322

Appendix 358

Methodology 358

Coverage 358

Secondary Research 358

Primary Research 358

Expert Panel Validation 358

Contact Us 358

Disclaimer 359

List of Tables

Merck & Co., Inc., Key Information 19

Merck & Co., Inc., Key Facts 19

Merck & Co., Inc.-Pipeline by Indication, 2015 21

Merck & Co., Inc.-Pipeline by Stage of Development, 2015 31

Merck & Co., Inc.-Monotherapy Products in Pipeline, 2015 32

Merck & Co., Inc.-Combination Treatment Modalities in Pipeline, 2015 33

Merck & Co., Inc.-Partnered Products in Pipeline, 2015 34

Merck & Co., Inc.-Partnered Products/ Combination Treatment Modalities, 2015 35

Merck & Co., Inc.-Out-Licensed Products in Pipeline, 2015 37

Merck & Co., Inc.-Out-Licensed Products/ Combination Treatment Modalities, 2015 38

Merck & Co., Inc.-Pre-Registration, 2015 40

Merck & Co., Inc.-Filing rejected/Withdrawn, 2015 41

Merck & Co., Inc.-Phase III, 2015 42

Merck & Co., Inc.-Phase II, 2015 44

Merck & Co., Inc.-Phase I, 2015 46

Merck & Co., Inc.-Preclinical, 2015 48

Merck & Co., Inc.-Discovery, 2015 50

Merck & Co., Inc.-Unknown, 2015 51

Merck & Co., Inc.-Pipeline by Target, 2015 233

Merck & Co., Inc.-Pipeline by Route of Administration, 2015 238

Merck & Co., Inc.-Pipeline by Molecule Type, 2015 240

Merck & Co., Inc.-Pipeline Products by Mechanism of Action, 2015 242

Merck & Co., Inc.-Recent Pipeline Updates, 2015 246

Merck & Co., Inc.-Dormant Developmental Projects,2015 309

Merck & Co., Inc.-Discontinued Pipeline Products, 2015 317

Merck & Co., Inc., Subsidiaries 333

List of Figures

Merck & Co., Inc.-Pipeline by Top 10 Indication, 2015 21

Merck & Co., Inc.-Pipeline by Stage of Development, 2015 31

Merck & Co., Inc.-Monotherapy Products in Pipeline, 2015 32

Merck & Co., Inc.-Combination Treatment Modalities in Pipeline, 2015 33

Merck & Co., Inc.-Partnered Products in Pipeline, 2015 34

Merck & Co., Inc.-Out-Licensed Products in Pipeline, 2015 37

Merck & Co., Inc.-Pipeline by Top 10 Target, 2015 232

Merck & Co., Inc.-Pipeline by Top 10 Route of Administration, 2015 238

Merck & Co., Inc.-Pipeline by Top 10 Molecule Type, 2015 239

Merck & Co., Inc.-Pipeline Products by Top 10 Mechanism of Action, 2015 241

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Current R&D Portfolio of Merck & Co., Inc.; Merck & Co., Inc. - Key Therapeutics; Merck & Co., Inc. - Pipeline Overview and Promising Molecules; Merck & Co., Inc. - News; Merck & Co., Inc. - Latest Updates; Merck & Co., Inc. - Pipeline; Merck & Co., Inc. - Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 102450
Site License
USD 3000 INR 204900
Corporate User License
USD 4500 INR 307350



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]